Abstract

We investigated the effects of silver nanoparticle (AgNP) exposure in three ovarian cancer cell lines (A2780, SKOV3, and OVCAR3). We found that AgNPs were highly cytotoxic toward A2780 and SKOV3 cells but OVCAR3 cells were less sensitive to AgNPs. In agreement with the cytotoxicity data, AgNPs caused DNA damage in A2780 and SKOV3 cells, but not in OVCAR3 cells. A2780 and SKOV3 showed higher levels of basal reactive oxygen species (ROS) relative to OVCAR3 cells. AgNP exposure increased ROS levels in both A2780 and SKOV3 cells, but not in OVCAR3 cells. We found that the heterogeneous cytotoxicity was specific to the uptake of intact particles and was not due to differences in sensitivity to silver ions. Furthermore, the combination of AgNPs and standard-of-care platinum therapy, cisplatin (cis-diamminedichloroplatinum(II), CDDP), was synergistic for treatment of A2780 andOVCAR3 cells and the combination of AgNPs and CDDP showed a favorable dose reduction in all cell lines tested. These results provide insight into potential applications of AgNPs for treatment of ovarian cancer.

Highlights

  • Ovarian cancer is the most lethal of all gynecological malignancies with a five-year survival rate of only 40% and is the fourth leading cause of female cancer deaths in the United States [1]

  • We examined the efficacy of AgNPs alone and in combination with CDDP for the treatment of ovarian cancer

  • Our results indicate that the relative sensitivity of ovarian cancer cell lines to AgNPs is heterogeneous

Read more

Summary

Introduction

Ovarian cancer is the most lethal of all gynecological malignancies with a five-year survival rate of only 40% and is the fourth leading cause of female cancer deaths in the United States [1]. DNA damaging drugs including cisplatin (CDDP) are among the most effective agents available to clinicians for treatment of ovarian cancer [3], but this efficacy comes at the expense of significant dose-limiting side effects [4]. Far, combined effects of AgNPs with cisplatin have not been assessed It remains unknown whether a synergistic or dose reducing interaction between AgNPs and cisplatin exists. We evaluate the efficacy of AgNPs for treatment of SKOV3, A2870, and OVCAR3 ovarian cancer cells, which are commonly used as models of high-grade serous carcinoma [30]. Because platinum-based chemotherapy remains a first-line choice for treatment of ovarian cancer, we subsequently determined the effect of combination therapy using both AgNPs and cisplatin to treat these cell lines. Our results provide insight into potential applications of AgNPs for treatment of ovarian cancer

Experimental Section
Results
Discussion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call